Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.

Autor:	van Kempen ZL; Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., van Dam KP; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands., Keijser JB; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Stalman EW; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands., Kummer LY; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Strijbis EM; Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Steenhuis M; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands.; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, The Netherlands., Ten Brinke A; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands., van Ham SM; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands.; Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands., Kuijpers T; Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands., Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Eftimov F; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands., Wieske L; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.; Department of Clinical Neurophysiology, St. Antonius Hospital, Nieuwegein, The Netherlands., Killestein J; Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Mar; Vol. 30 (3), pp. 443-447. Date of Electronic Publication: 2023 Nov 09.
DOI:	10.1177/13524585231207761
Abstrakt:	Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear. Methods: Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination. Results: Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant. Conclusion: Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: FE and TK report (governmental) grants from ZonMw to study immune response after SARS-CoV-2 vaccination in auto-immune diseases. FE also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and GBS-CIDP Foundation; consulting fees from UCB Pharma and CSL Behring; honoraria from Grifols. JK has speaking relationships with Merck Serono, Biogen Idec, TEVA, Sanofi, Genzyme, Roche, and Novartis; Amsterdam UMC, location VUmc, MS Center Amsterdam has received financial support for research activities from Merck Serono, Bayer Schering Pharma, Biogen Idec, GlaxoSmithKline, Roche, Teva, Sanofi, Genzyme, GlaxoSmithKline, and Novartis. No other disclosures were reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu